Cooperation between tumor necrosis factor (TNF) and platelet-activating factor (PAF) in the inflammatory response
- PMID: 1966813
Cooperation between tumor necrosis factor (TNF) and platelet-activating factor (PAF) in the inflammatory response
Abstract
In this paper we have examined the cooperation between TNF and PAF in the generation of superoxide anion (O2-) in vitro by polymorphonuclear cells (PMNs), as well as their ability to induce joint inflammation when injected into the knee of healthy rabbits. TNF and PAF directly stimulated the generation of a small amount of O2- by PMNs. TNF pretreatment of PMNs induced a certain synergy in the O2- production, when these cells were later stimulated with PAF. When PAF receptor antagonists were added, the O2- release was inhibited. The injection of either TNF or PAF into the knee joint of normal rabbits induced a dose-dependent accumulation of leukocytes in the synovial cavity 24 h after administration. When TNF was administered 1 h before PAF, a synergistic response in the accumulation of leukocytes in the joint fluid was noted. The administration of BN 52726 by the intraperitoneal route markedly inhibited the cell accumulation induced by TNF and PAF. Histological signs of inflammation were noted in the synovial lining of joints injected with TNF and PAF. These results suggest that TNF can amplify the inflammatory response induced by PAF. PAF antagonists can inhibit this effect and thus may be of therapeutic value in different pathological situations.
Similar articles
-
Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins.J Lipid Mediat. 1990;2 Suppl:S1-4. J Lipid Mediat. 1990. PMID: 1966810
-
Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits.Clin Exp Immunol. 1992 May;88(2):318-23. doi: 10.1111/j.1365-2249.1992.tb03080.x. Clin Exp Immunol. 1992. PMID: 1315229 Free PMC article.
-
Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.Biochem Biophys Res Commun. 1987 Nov 13;148(3):1412-7. doi: 10.1016/s0006-291x(87)80289-9. Biochem Biophys Res Commun. 1987. PMID: 2825685
-
The role of platelet-activating factor (PAF) in interstitial pulmonary disease.J Investig Allergol Clin Immunol. 1994 May-Jun;4(3):149-57. J Investig Allergol Clin Immunol. 1994. PMID: 7981886 Review.
-
Platelet-activating factor antagonists as therapeutic strategy in sepsis.Prog Clin Biol Res. 1994;388:277-93. Prog Clin Biol Res. 1994. PMID: 7831364 Review. No abstract available.
Cited by
-
Effects of esculentoside A on turnour necrosis factor production by mice peritoneal macrophages.Mediators Inflamm. 1992;1(6):375-7. doi: 10.1155/S0962935192000565. Mediators Inflamm. 1992. PMID: 18475487 Free PMC article.
-
Significance of lipid mediators in corneal injury and repair.J Lipid Res. 2010 May;51(5):879-91. doi: 10.1194/jlr.R001347. Epub 2009 Nov 3. J Lipid Res. 2010. PMID: 19965607 Free PMC article. Review.
-
Recombinant tumour necrosis factor-alpha and platelet-activating factor synergistically increase intercellular adhesion molecule-1 and E-selectin-dependent neutrophil adherence to endothelium in vitro.Immunology. 1996 Mar;87(3):454-60. Immunology. 1996. PMID: 8778033 Free PMC article.
-
Inhibitory effect of esculentoside A on tumour necrosis factor alpha production by human monocytes.Mediators Inflamm. 1996;5(4):292-4. doi: 10.1155/S0962935196000427. Mediators Inflamm. 1996. PMID: 18475742 Free PMC article.
-
PAF. A review of its effects, antagonists and possible future clinical implications (Part II).Drugs. 1991 Aug;42(2):174-204. doi: 10.2165/00003495-199142020-00002. Drugs. 1991. PMID: 1717219 Review. No abstract available.